Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug

Quince Therapeutics Inc. has announced the completion of patient visits in its pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate (eDSP) for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved treatments. The international, multicenter, randomized, double-blind, placebo-controlled study enrolled 105 participants and was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The primary efficacy endpoint is based on changes in the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) from baseline to the last efficacy visit. Quince Therapeutics expects to report topline results from the trial in the middle of the first quarter of 2026. Results have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215328276) on December 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)